Urologists discuss why kidney stones should be considered “a mainstream public health problem”
December 16th 2021“[Kidney stones] really seems like something that we should be devoting significant resources and effort to trying to figure out the root causes and also better treatments and therapies for,” says Jonathan E. Shoag, MD.
What clinicians can do to mitigate the risk of sepsis after ureteroscopy
December 15th 2021“We should really try to adapt, know what we're doing to the specific patient based on their risk factors, prepare them appropriately, and understand that it's a dangerous complication. We should do everything we can to prevent it,” says Naeem Bhojani, MD, FRCSC.
Rezum therapy: Why it should be considered in large prostates
November 29th 2021“While this study does offer a lot of promise for the treatment options that we can offer to these patients, it does also highlight the need for further prospective trials to evaluate the efficacy of this treatment, as well as the treatments of all the different surgical options available to patients who are suffering from BPH,” says Evan Garden.
Aquablation therapy as a discussion point in patient counseling
November 26th 2021“I think the key elements are that you should know about Aquablation if you are treating BPH in consideration for your patients and care, especially those who are looking for a more durable response and to maintain their ejaculation,” says Kevin Zorn, MD, FRCSC, FACS.
How plant-based diets are lowering the risk of aggressive prostate cancer
November 22nd 2021“I believe that at every stage, it's very important that we focus on healthful lifestyle behaviors because we can improve [urologic patients’] overall survival and their cardiovascular health,” says Stacy Loeb, MD, PhD, MSc.
Dr. Ginsberg urges clinicians to consider onabotulinumtoxinA for OAB and urinary incontinence
November 17th 2021“Men do well and they don't have a really high risk of outcomes that we don't want them to have and that patients don't want to have, which is really the need to catheterize,” says David A. Ginsberg, MD.
Dr. Bander gives an overview of PSMA-PET imaging innovations
November 16th 2021“It's very clear that PSMA-PET imaging is having…a transformative impact on our ability to image metastatic disease, in that it is much more sensitive than we've had for the last 50 plus years—and also, 98% specific,” says Neil H. Bander, MD.
Goals of ProsTIC's theranostics research in prostate cancer
November 15th 2021“We hope to further investigate next-generation PSMA-targeting molecules, develop new biomarkers to try to predict and monitor response to these novel therapies, optimize combinations with other treatments, and do some discovery research, including artificial intelligence [and] deep learning of our images,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.
Dr. Hofman on the potential of LuPSMA in advanced prostate cancer
November 11th 2021“We expect an outcome from the FDA next year and if that's positive, we expect global, widespread availability of this as a new option for men with metastatic castration-resistant prostate cancer,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.
The ENGAGEMENT study and virtual genetics board
November 11th 2021“There really are many considerations regarding germline testing, results interpretation, implications for treatment or screening, and the familial hereditary implications of this whole field. Because of that, understanding the role of genetic counseling is critical, and also understanding the interplay with various somatic testing approaches is also really important,” says Veda N. Giri, MD.